Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Drug Manufacturers Sue HHS OIG Over Denial Of Part D Patient Assistance Program

Executive Summary

Complaint against the US government watchdog agency disputes its conclusion that a proposed cost sharing assistance program in Medicare to be funded by a coalition of cancer drug manufacturers would likely violate the federal anti-kickback statute.

You may also be interested in...

Cancer Rx Assistance Program Proposed For Part D Fails In Court As OIG Win Streak Continues

Defeat for group covering about 50 drugs from various sponsors is in line with an earlier court battle fought, and lost, by Pfizer and means the OIG will continue to scrutinize cost sharing assistance programs with a narrow view of what comports with the federal Anti-Kickback Statute.

Pfizer Case May Be ‘Only Chance’ For Supreme Court To Save Co-Pay Charity Assistance Programs

Based on HHS’ interpretation of the Anti-Kickback Statute, 11 pharma companies, including Pfizer, have reached settlements on their programs offering financial assistance to Medicare patients trying to access treatment. Now the firm hopes its tafamidis program will help it win in court.

Cost Sharing Program In Part D From Coalition Of Cancer Drug Manufacturers Rebuffed By OIG

Federal watchdog group acknowledges proposed assistance program aligns with comments in a 2005 OIG advisory bulletin on patient assistance programs in Medicare Part D, but maintains the bulletin should not serve as a roadmap for a compliant program in this case.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts